Dose-volume predictors for radiation esophagitis in breast cancer patients undergoing hypofractionated regional nodal radiotherapy
Dan-Qiong Wang,Na Zhang,Li-Hua Dong,Ya-Hua Zhong,Hong-Fen Wu,Qiu-Zi Zhong,Jing Jin,Xiao-Rong Hou,Hao Jing,Yu Tang,Chen Hu,Yong-Wen Song,Yue-Ping Liu,Shu-Nan Qi,Yuan Tang,Ning-Ning Lu,Bo Chen,Yi-Rui Zhai,Wen-Wen Zhang,Ning Li,Hui Fang,Ye-Xiong Li,Shu-Lian Wang
DOI: https://doi.org/10.1016/j.ijrobp.2023.03.060
2023-03-31
Abstract:Purpose To assess the incidence and dose-volume predictors of radiation esophagitis (RE) in breast cancer patients undergoing hypofractionated regional nodal irradiation (RNI). Methods Eligible patients were included who received intensity-modulated radiotherapy (RT) at the chest wall, the supraclavicular/infraclavicular fossa, level II axilla, and/or the internal mammary chain after mastectomy. The prescribed dose was 43.5 Gy in 15 fractions. RE was evaluated weekly during RT and at 1 and 2 weeks, followed by 3 and 6 months after RT, and was graded according to the Common Toxicity Criteria for Adverse Events v3.0. The esophagus was contoured from the lower border level of the cricoid cartilage to the lower margin of the aortic arch. Esophageal total volume, mean dose (Dmean), maximum dose (Dmax), and the relative and absolute volumes receiving at least 5-45 Gy by 5 Gy increments (RV5–RV45 and AV5–AV45) were evaluated. Univariable and multivariable logistics regression analyses were performed to determine risk factors for RE, and receiver operating characteristic curves were obtained to identify the thresholds of esophageal dosimetric parameters. Results In total , 298 patients were included between May 8, 2020 and January 5, 2022 (minimum post-RT follow-up: 6 months). Grade 2 and 3 RE incidence was 40.9% (122/298) and 0.3% (1/298), respectively. No grade 4 or 5 RE was observed. Esophageal RV10-RV40 and AV35-AV40 were significantly associated with the risk of ≥grade 2 RE after adjusting for tumor laterality and internal mammary nodal irradiation. RV25 and AV35 were optimum dose-volume predictors for ≥grade 2 RE at thresholds 20% for RV25 (35.9% vs. 60.9%, p = .04) and 0.27 mL for AV35 (31.0% vs. 54.6%, p = .04). Conclusion RE is common in breast cancer patients undergoing hypofractionated RNI. Maintaining the upper esophageal V25 at <20% and V35 at <0.27 mL may decrease the risk of RE.
oncology,radiology, nuclear medicine & medical imaging